in Healthcare IT, News
CSRA Subsidary’s Plague Vaccine Receives FDA Orphan Drug Designation
A plague vaccine being developed by a CSRA subsidiary has received orphan drug status from the U.S. Food and Drug Administration as a treatment for pre-exposure prophlaxis of Yersinia pestis infection. CSRA said Wednesday its DynPort Vaccine Company works with the Defense Department on the development of the recombinant rF1V plague vaccine that will be added to the DoD’s medical countermeasures portfolio […] More